Search
Incannex Healthcare Inc
IXHLAdd to Watchlist
3.970USD
+0.260+7.01%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
54.32MMarket Cap
LossP/E TTM
More Details of Incannex Healthcare Inc Company
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.
Incannex Healthcare Inc Info
Ticker SymbolIXHL
Company nameIncannex Healthcare Inc
IPO dateMar 18, 2022
CEOLatham (Joel)
Number of employees12
Security typeOrdinary Share
Fiscal year-endMar 18
Address8 Century Circuit
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryAustralia
Postal code2153
Phone61409840786
Website
Ticker SymbolIXHL
IPO dateMar 18, 2022
CEOLatham (Joel)
Company Executives of Incannex Healthcare Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
806.21K
+93.48%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
85.81K
+99.30%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
81.89K
+68.67%
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
65.26K
+86.17%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
21.32K
--
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
806.21K
+93.48%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
85.81K
+99.30%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
81.89K
+68.67%
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
65.26K
+86.17%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
21.32K
--
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
FAQs
Who are the top five shareholders of Incannex Healthcare Inc?
The top five shareholders of Incannex Healthcare Inc are: Mr. Joel Latham
How many institutions hold shares of Incannex Healthcare Inc (IXHL)?
As of 2026Q1, 52 institutions hold shares of Incannex Healthcare Inc, with a combined market value of approximately 501.46K, accounting for 3.59% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 248085.00.